CRIS Current Research Information System

COLANGELI, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.603
EU - Europa 957
AS - Asia 567
AF - Africa 91
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
OC - Oceania 1
Totale 3.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.598
GB - Regno Unito 233
CN - Cina 215
SE - Svezia 215
IT - Italia 154
SG - Singapore 147
DE - Germania 117
VN - Vietnam 113
IN - India 62
IE - Irlanda 54
TG - Togo 50
UA - Ucraina 42
RU - Federazione Russa 41
FR - Francia 33
BG - Bulgaria 24
JO - Giordania 24
EE - Estonia 21
ZA - Sudafrica 20
CI - Costa d'Avorio 12
NG - Nigeria 8
FI - Finlandia 7
CH - Svizzera 6
BE - Belgio 5
MX - Messico 4
EU - Europa 3
ID - Indonesia 3
CL - Cile 2
AU - Australia 1
DK - Danimarca 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
JP - Giappone 1
LB - Libano 1
MS - Montserrat 1
NL - Olanda 1
RO - Romania 1
SC - Seychelles 1
Totale 3.224
Salva come PNG Salva come JPEG
Città #
Southend 210
Fairfield 183
Chandler 162
Singapore 137
Santa Clara 124
Ashburn 114
Woodbridge 104
Seattle 99
Houston 88
Wilmington 69
Princeton 63
Cambridge 58
Dublin 54
Dong Ket 52
Bologna 51
Lomé 50
Ann Arbor 47
Boardman 40
Nanjing 29
Florence 26
Westminster 26
Amman 24
Berlin 24
Sofia 24
Padova 20
Jacksonville 18
Jinan 14
Saint Petersburg 14
Hebei 13
San Diego 13
Turin 13
Abidjan 12
Beijing 12
Dearborn 12
New York 12
Redmond 12
Changsha 9
Des Moines 9
Olalla 9
Shenyang 9
Abeokuta 8
Guangzhou 7
Los Angeles 7
Nanchang 7
Ningbo 7
Tianjin 7
Zhengzhou 7
Bremen 6
Milan 6
Rome 6
Bern 5
Brussels 5
Bühl 5
Falls Church 5
Helsinki 5
Jiaxing 5
Lanzhou 5
Shanghai 5
Taizhou 5
Hangzhou 4
Shenzhen 4
Shijiazhuang 4
Hefei 3
Mountain View 3
Mülheim 3
Norwalk 3
Wuhan 3
Appleton 2
Haikou 2
Hanover 2
Islington 2
London 2
Montelupo Fiorentino 2
Munich 2
Orange 2
Phoenix 2
Poggibonsi 2
Redwood City 2
Taiyuan 2
Tijuana 2
Xi'an 2
Xiamen 2
Amsterdam 1
Andover 1
Avola 1
Bay Springs 1
Benevento 1
Buffalo 1
Carol Stream 1
Chicago 1
Chiswick 1
Copenhagen 1
Dalian 1
Dallas 1
Dongguan 1
Foshan 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Genoa 1
Totale 2.247
Salva come PNG Salva come JPEG
Nome #
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 140
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 132
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 132
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 131
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 128
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 127
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 126
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 121
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 115
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 115
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 115
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. 115
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 114
null 113
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 112
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 111
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 110
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 110
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc) 107
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 107
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 102
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 99
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 98
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 97
Raltegravir use prospectically assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile 89
Integration among hospital pharmacists and infectious diseases physicians in the outpatient management of HIV infection 74
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 74
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up 73
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 67
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 56
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 44
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 26
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 15
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 9
Totale 3.304
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.972
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.972
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020482 0 0 0 0 0 71 91 96 110 57 25 32
2020/2021365 89 22 10 13 10 15 5 10 36 20 15 120
2021/2022649 54 27 35 79 66 26 12 29 21 114 108 78
2022/2023694 51 102 23 94 44 44 11 62 148 19 67 29
2023/2024211 14 31 9 33 10 52 8 21 7 11 9 6
2024/2025431 33 70 57 69 173 29 0 0 0 0 0 0
Totale 3.304